PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING KELOIDS, HYPERTROPHIC SCARS AND WOUNDS, AND FOR PROVIDING IMPROVED SKIN CARE
A method for treating keloids, hypertrophic scars and/or wounds and/or other skin conditions, the method comprising: delivering a pharmaceutically effective amount of a pharmaceutical composition to the keloids, hypertrophic scars and/or wounds and/or other skin conditions, wherein the pharmaceutical composition comprises a mixture of cross-linked glycosaminoglycans and taurolidine and/or one or more taurolidine derivatives.
1 . A method for treating keloids, hypertrophic scars and/or wounds and/or other skin conditions, the method comprising:
delivering a pharmaceutically effective amount of a pharmaceutical composition to the keloids, hypertrophic scars and/or wounds and/or other skin conditions, wherein the pharmaceutical composition comprises a mixture of cross-linked glycosaminoglycans and taurolidine and/or one or more taurolidine derivatives.
2 . A method according to claim 1 wherein the glycosaminoglycans used to form the cross-linked glycosaminoglycans comprise at least one from the group consisting of hyaluronic acid, heparin, heparin sulfate, chondroitin sulfate and sulfated polysaccharides.
3 . A method according to claim 1 wherein the cross-linked glycosaminoglycans are formed from a single type of glycosaminoglycans.
4 . A method according to claim 1 wherein the cross-linked glycosaminoglycans are formed from at least two different types of glycosaminoglycans.
5 . A method according to claim 1 wherein the cross-linked glycosaminoglycans comprise cross-linked hyaluronic acid.
6 . A method according to claim 5 wherein the cross-linked hyaluronic acid is approximately 0.1% to approximately 20% by weight of the pharmaceutical composition.
7 . A method according to claim 1 wherein the cross-linked glycosaminoglycans comprise cross-linked heparin.
8 . A method according to claim 7 wherein the cross-linked heparin is approximately 0.10% to approximately 3.0% by weight of the pharmaceutical composition.
9 . A method according to claim 1 wherein the cross-linked glycosaminoglycans are cross-linked by chemical cross-linking, chelate formation, complex formation or salt formation.
10 . A method according to claim 1 wherein the taurolidine and/or the one or more taurolidine derivatives is approximately 1% to approximately 10% by weight of the pharmaceutical composition.
11 . A method according to claim 1 wherein the pharmaceutical composition further comprises a carrier within which the mixture of the cross-linked glycosaminoglycans and taurolidine and/or one or more taurolidine derivatives resides.
12 . A method according to claim 11 wherein the carrier comprises water.
13 . A method according to claim 1 wherein the pharmaceutical composition is in the form of a solution.
14 . A method according to claim 1 wherein the pharmaceutical composition is in the form of a gel.
15 . A method according to claim 1 wherein the pharmaceutical composition is in the form of a powder.
16 . A method according to claim 1 wherein the pharmaceutical composition is delivered by injection.
17 . A method according to claim 1 wherein the pharmaceutical composition is delivered by topical application.
18 . A pharmaceutical composition comprising:
a pharmaceutically effective amount of a mixture of cross-linked glycosaminoglycans and taurolidine and/or one or more taurolidine derivatives.
19 . A pharmaceutical composition according to claim 18 wherein the glycosaminoglycans used to form the cross-linked glycosaminoglycans comprise at least one from the group consisting of hyaluronic acid, heparin, heparin sulfate, chondroitin sulfate and sulfated polysaccharides.
20 . A pharmaceutical composition according to claim 18 wherein the cross-linked glycosaminoglycans are formed from a single type of glycosaminoglycans.
21 . A pharmaceutical composition according to claim 18 wherein the cross-linked glycosaminoglycans are formed from at least two different types of glycosaminoglycans.
22 . A pharmaceutical composition according to claim 18 wherein the cross-linked glycosaminoglycans comprise cross-linked hyaluronic acid.
23 . A pharmaceutical composition according to claim 22 wherein the cross-linked hyaluronic acid is approximately 0.1% to approximately 20% by weight of the pharmaceutical composition.
24 . A pharmaceutical composition according to claim 18 wherein the cross-linked glycosaminoglycans comprise cross-linked heparin.
25 . A pharmaceutical composition according to claim 24 wherein the cross-linked heparin is approximately 0.10% to approximately 3.0% by weight of the pharmaceutical composition.
26 . A pharmaceutical composition according to claim 18 wherein the cross-linked glycosaminoglycans are cross-linked by chemical cross-linking, chelate formation, complex formation or salt formation.
27 . A pharmaceutical composition according to claim 18 wherein the taurolidine and/or the one or more taurolidine derivatives is approximately 1% to approximately 10% by weight of the pharmaceutical composition.
28 . A pharmaceutical composition according to claim 18 wherein the pharmaceutical composition further comprises a carrier within which the mixture of the cross-linked glycosaminoglycans and taurolidine and/or one or more taurolidine derivatives resides.
29 . A pharmaceutical composition according to claim 28 wherein the carrier comprises water.
30 . A pharmaceutical composition according to claim 18 wherein the pharmaceutical composition is in the form of a solution.
31 . A pharmaceutical composition according to claim 18 wherein the pharmaceutical composition is in the form of a gel.
32 . A pharmaceutical composition according to claim 18 wherein the pharmaceutical composition is in the form of a powder.